wow. let me get one thing straight here. FDA approval is not the end point. It is only a stepping stone for us to go international. The end point here is that the whole world, USA, China, India and etc use this app for ALL respiratory diseases (not only athma) and we are sitting at $100 per share and taking dividend per quarterly. That is the end point. Maybe in 5 years?
Who's the WHO?, page-23
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)